Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + gemcitabine (Blatam)
- Development stage
- Unknown
- Lead developer
- BLATAM
- Modality
- Small Molecules
- Administration
- Intravesical
01
Overview
Docetaxel + gemcitabine is a combination chemotherapy regimen used for the treatment of non-muscle invasive bladder cancer (NMIBC), especially in patients who are unresponsive to or have been exposed to Bacillus Calmette-Guérin (BCG) therapy. Gemcitabine acts as a nucleoside metabolic inhibitor that interferes with DNA synthesis, while docetaxel is a taxane that promotes microtubule assembly and inhibits disassembly, leading to mitotic arrest. In the specific clinical trial context provided, this combination is administered intravesically in conjunction with systemic pembrolizumab to treat high-risk NMIBC.
- Other names
- gemcitabine and docetaxelintravesical gemcitabine/docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on docetaxel + gemcitabine (Blatam).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + gemcitabine (Blatam).